Literature DB >> 19190631

Overexpressed vs mutated Kras in murine fibroblasts: a molecular phenotyping study.

M Horsch1, C V Recktenwald, S Schädler, M Hrabé de Angelis, B Seliger, J Beckers.   

Abstract

Ras acts in signalling pathways regulating the activity of multiple cellular functions including cell proliferation, differentiation, and apoptosis. Amino-acid exchanges at position 12, 13, or 61 of the Kras gene convert the proto-oncogene into an activated oncogene. Until now, a direct comparison of genome-wide expression profiling studies of Kras overexpression and different Kras mutant forms in a single assay system has not been carried out. In our study, we focused on the direct comparison of global gene expression effects caused by mutations in codon 12 or 13 of the Kras gene and Kras overexpression in murine fibroblasts. We determined Kras cellular mRNA, Ras protein and activated Ras protein levels. Further, we compared our data to the proteome analysis of the same transfected cell lines. Both overexpression and mutations of Kras lead to common altered gene expression patterns. Only two genes, Lox and Col1a1, were reversely regulated in the Kras transfectants. They may contribute to the higher aggressiveness of the Kras codon 12 mutation in tumour progression. The functional annotation of differentially expressed genes revealed a high frequency of proteins involved in tumour growth and angiogenesis. These data further support the important role of these genes in tumour-associated angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19190631      PMCID: PMC2653730          DOI: 10.1038/sj.bjc.6604882

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


The Ras gene family (Hras, Nras, Kras4A, and 4B) encodes small intracellular, membrane-associated proteins, which are regulated by the GDP/GTP cycle. Switching between the active GTP-bound and the inactive GDP-bound state is regulated by GTPase-activating proteins (Marshall, 1995) and guanine nucleotide exchange factor proteins (Downward, 1996). Activated Ras stimulates a cascade of serine/threonine kinases that control diverse biological processes including cell proliferation, differentiation, or apoptosis. The Kras proto-oncogene becomes oncogenic by single point mutations in codon 12 or 13, which locks the mutated Kras gene product in the GTP-bound activated state (Barbacid, 1987). These mutant forms of Ras transduce signals that result in oncogenic transformation, angiogenesis, invasion, and metastasis by downstream pathways (Olson and Marais, 2000). Frequently, activated Kras oncogenes were identified in human bladder, lung, breast, and kidney cancer (Fujita ; Solana ; Yuasa ; Orntoft and Wolf, 1998) as well as in carcinoma of the colon (Capon ) and in acute myeloid leukaemia (Neubauer ). In addition to the Ras mutants, the generation of multiple Kras gene copies has been detected in murine mammary tumours. Despite the prevalent role of Kras mutations in tumorigenesis, only a few studies have assessed genome-wide transcriptional changes in Kras-transfected cell lines. Transcript expression analyses have been performed comparing normal rat embryo fibroblasts and cells transformed by mutant Hras, Kras, and Nras (Zuber ). Neoplastic transformation driven by the mutated Kras oncogene was analysed by expression profiling of rat ovarian epithelial cells (Tchernitsa ). Differentially regulated genes in response to an activated mutation in Kras or Hras were analysed in a colon adenoma cell line, employing microarray technology (Roberts ). Transcriptome analysis described changes in gene expression levels of embryonic mouse fibroblasts carrying a mutation in codon 12 of Kras (Vasseur ). These studies showed that genes regulated by the activated forms of Ras involve cellular processes associated with tumorigenesis. Clinical studies have suggested that tumour cells carrying Kras codon 13 mutations are less aggressive than those with codon 12 mutations (Bazan ). Different levels of aggressiveness in the transforming phenotype induced by mutations in Kras codon 12 or 13 and the overexpression of the Kras proto-oncogene in transfected NIH3T3 cells were also described (Guerrero ). These results suggest that despite many similarities in their oncogenic capacity, the different mutant forms and Ras overexpression may activate also distinct downstream targets that are responsible for the different oncogenic capacities. So far, a direct comparison of genome-wide transcript profiles of different Kras mutant forms and Kras overexpression in a single assay system has not been performed. Because of these reasons we used genome-wide expression profiling analysis to investigate differences among samples of murine fibroblasts carrying Kras codon 12 or 13 mutations and cells that constitutively overexpress the wild-type (wt) Kras gene. In wt Kras, the codons at position 12 and 13 encode two adjacent glycines located in the GDP/GTP-binding site of Ras. The G12V and G13D mutations lead to the constitutive binding of GTP and as a consequence to a permanent activation of the signal transduction cascade. We analysed Kras NIH3T3 transfectants carrying mutations at codon 12 (KrasG12V) or 13 (KrasG13D) or overexpress wt Kras (Krasoe). The non-transfected parental (NIH3T3) and mock-transfected cells (Krasmock) served as controls. The total amounts of Kras cellular RNA, Ras, and active Ras proteins were measured in all cell lines. Hierarchical clustering of differentially expressed genes was used to compare the gene expression patterns of the distinct transfected cell lines. Furthermore, we analysed the functional classification of the regulated genes and their role in distinct carcinogenic processes.

Materials and methods

Kras-transfected cell lines

Wildtype and mutated Kras genes were amplified by RT–PCR from human cell lines and cloned into the pIREShyg expression vector of murine NIH3T3 fibroblast as recently described (Recktenwald ). Total RNA from transfecants and non-transfected cell lines was obtained according to the manufacturer's protocols using RNeasy Midi kits (Qiagen, Hilden, Germany). The RNA concentration was calculated from OD260/280 readings and 2 μg RNA aliquots were run on formaldehyde agarose gels to check for RNA integrity.

DNA microarrays

Glass cDNA chips were produced as recently described (Horsch ). A full description of the approximate 21 000 probes on the microarray is available in the GEO database under GPL3697. The expression data of Kras-transfected NIH3T3 cell lines have been submitted to the GEO database (GSE8372). Four independent dual colour hybridisations including two dye swap experiments were performed with RNA from each of the four transfected cell lines (in total n=16) using non-transfected cells as reference. All experiments were performed according to a modified TIGR protocol (Horsch ). Slides were scanned with a GenePix 4000A microarray scanner and the images analysed with the GenePix Pro6.1 image processing software (Molecular Devices, CA, USA).

Analysis of gene expression levels

Statistical analyses were performed with TIGR Microarray Data Analysis System (TM4) including MIDAS (Microarray Data Analysis System; Quackenbush, 2002) for normalisation and SAM (significant analysis of microarrays; Tusher ) for identification of genes with significant differential regulation. Cluster analyses were employed using HCL (hierarchical cluster analyses; Eisen ). Expression data were processed (MIDAS) applying a total intensity normalisation, and low-quality array elements were eliminated by several filtering methods, such as background checking for both channels with a signal/noise threshold of 2.0, one bad tolerance policy parameter, and a flip dye consistency check. First, a multiclass SAM analysis for the identification of significant gene regulation in Krasoe, KrasG12V, and KrasG13D transfectants was performed. Therefore, three groups of experiments were specified: Four chip hybridisations of Krasoe-, KrasG12V-, and KrasG13D-transfected cell lines built a separate group. Genes were considered as significant if they were differentially regulated in at least two of the three specified groups. Second, significantly regulated genes in the Krasmock transfectants were identified by one class analysis. The percentage of genes identified by chance is the false discovery rate (FDR), which was estimated by calculating 1000 permutations. For hierarchical clustering of expression profiles, the average-linkage method was applied. As distance metric the Euclidean distance was chosen.

In silico pathway analysis

For in silico analysis of differentially expressed genes, EASE, a module of the DAVID database (Dennis ) assigning genes to gene ontology (GO) functional categories, was employed. EASE analysis, including a Bonferroni multiplicity correlation, evaluated the set of differentially expressed genes for overrepresentation of two categories of GO terms: biological processes and molecular functions.

Real-time quantitative (qRT) PCR

Ten differentially expressed genes (Col6a1, Fapb5, Ftl1, H3f3b, Lox, Prss23, S100a11, Sparc, Sqstm1, and Vim) as well as the expression levels of Kras were assessed by qRT–PCR performed in a 7700 SDS thermal cycler using the SYBR Green I system (Applied Biosystems, Darmstadt, Germany). Two target-specific primer pairs were designed for each selected gene using OligoPerfect™ Designer (Invitrogen, Karlsruhe, Germany) and purchased from Sigma (Taufkirchen, Germany). Duplicate crossing points per marker were averaged per independent experiment for both primer pairs (n=16, including two cDNA dilutions). Values were normalised to levels of β-actin.

Analysis of total and activated Ras expression levels

Expression levels of active GTP-bound Ras as well as total Ras were determined as described previously (Recktenwald ). Activated Ras molecules were isolated with a selective pull-down assay with glutathione S-transferase-Raf1–Ras-binding domain fusion protein (GST-Raf1–RBD) using the EZ-Detect™-Ras-Activation Kit (Perbio, Bonn, Germany). Cells were harvested, lysed, and incubated with GST-Raf1-RBD and one swell gel glutathione disc. After three washing steps with lysis buffer, GTP-bound Ras was eluted with SDS sample buffer (Laemmli UK 1970) and boiled. Equal protein amounts were separated on 12% SDS polyacrlyamide gels and transferred onto nitro cellulose membranes. Ras molecules were visualised by incubation of the membranes with anti-Ras primary antibody followed by incubating with a horse-raddish peroxidase-coupled antimouse secondary antibody. The complexes were detected using the enhanced chemiluminescence Kit (Perbio).

Results

Morphological changes of the Kras transfectants

As recently described (Recktenwald ), the morphology of Kras transfectants was characterised by a more spindle-like shape and appeared less flat as parental and mock control cells. Furthermore, the Kras transfectants exhibit long cell extensions suggesting the development of filo- and/or lamellipodiae. These morphological changes are most prominent in Kras mutants and weaker in the Krasoe transfectants. In addition, all Kras transfectants show an increased cell growth as indicated by reduced doubling times (data not shown).

Kras transcript and protein expression levels

We measured the levels of Kras gene expression in all cell lines investigated by qRT–PCR. No changes in the total amount of Kras in Krasmock, KrasG12V, and KrasG13D cell lines compared with the non-transfected cell lines were identified (Figure 1A). The overexpression of Kras was only detected in Krasoe transfectants. Additionally, for the determination of the Ras protein expression, the activation status as well as the total cellular Ras expression of the different Ras oncoproteins was analysed by western blot analysis. KrasG12V and KrasG13D cells showed similar increased levels of total cellular Ras proteins when compared with the parental- (NIH3T3) and mock-transfected cell lines (Figure 1B). Furthermore, activated GTP-bound Ras was only detectable in these two cell lines (Figure 1B). Although the level of Kras transcript was not influenced by the mutations, the protein levels and its activity were increased in KrasG12V and KrasG13D cells. Kras overexpression on transcript level had no influence on cellular protein or active Ras protein level.
Figure 1

Kras transcript and protein expression levels. (A) Kras expression levels were measured by qRT–PCR. The results are given as the linear ratio of expression levels relative to the expression level of Kras expression in the non-transfected NIH3T3 cells. Numbers on the Y axis show the fold changes of gene expression levels. (B) Quantification of total Ras and activated Ras molecules by western blotting. β-actin served as loading control.

Comparative analysis of gene expression patterns

In this study, a comparison of global gene expression effects caused by mutations in codon 12 (KrasG12V) or 13 (KrasG13D) of the Kras proto-oncogene and Kras overexpression (Krasoe) in murine fibroblasts was performed. A multiclass SAM analysis identified 61 genes significantly regulated in at least two out of the three Krasoe, KrasG12V, and KrasG13D transfectants compared with non-transfected parental cells. Significance was assigned using an FDR threshold of <0.05 in conjunction with a ratio threshold of >1.5. In all, 17 out of 34 genes significantly regulated in Krasmock transfectants were also identified as differentially expressed in the three experimental cell lines (KrasG12V, KrasG13D, and Krasoe). On the basis of the rational that the altered expression level of these 17 genes was most likely caused by the transfection procedure itself, these genes were excluded from the subsequent hierarchical clustering and GO term analyses. Hierarchical cluster analysis was applied on the remaining 44 genes differentially expressed in at least two out of three experimental Kras transfectants, but not in the Krasmock cell line. The cluster algorithm classified the selected genes into three groups based on the similarities in expression patterns across the transfectants (Figure 2): the first group comprises upregulated genes (Figure 2, indicated as ‘A’), the second group comprises the downregulated genes (Figure 2, indicated as ‘B’) in the Krasoe-, KrasG12V-, and/or KrasG13D-transfected cell lines. The genes of the subgroup C were upregulated in Krasoe, downregulated in KrasG12V, and showed no regulation in KrasG13D (Figure 2, indicated as ‘C’). For Lox, both non-overlapping sequences represent similar values of transcriptional changes compared with the reference cells. Increased expression levels of 1.8/1.9-fold changes for Lox/Col1a1 were found in Krasoe. In KrasG12V, Lox/Col1a1 was downregulated (2.1/1.6-fold changes). Ratios of −1.07 for Lox and 1.13 for Col1a1 in KrasG13D indicate no significant differences between this transfected cell line and the reference. These data indicate that the overexpression of Kras (Krasoe) influences the regulation of genes similarly to the regulation induced by the mutations in codon 12 or 13 of Kras. Yet, cluster analysis revealed more similarities between gene expression patterns of KrasG12V and KrasG13D transfectants (Figure 2) when compared with Krasoe cells.
Figure 2

Hierarchical cluster analysis. Hierarchical cluster analysis was performed using gene expression data from 44 probes significantly differentially expressed in at least two out of three transfected NIH3T3 cell lines. For each gene, red indicates higher expression relative to the control and green indicates lower gene expression. Grey boxes represent genes with expression levels below detection limits. Several subgroups of genes with similar expression patterns are colour coded to the left of the heat plots.

Changes in the expression levels of 10 genes (Col6a1, Fabp5, Ftl1, H3f3b, Lox, Prss23, S100a11, Sparc, Sqstm1, and Vim) identified as regulated in the microarray experiments were validated by qRT–PCR. With the exception of H3f3b, the tendency in terms of up- and downregulation was confirmed in all four cell lines (Figure 3).
Figure 3

Validation of microarray experiments. qRT–PCR from 10 regulated genes in the four transfected cell lines compared with microarray data. Results are illustrated as ratios of expression relative to the expression of the reference (non-transfected NIH3T3 cells). Black columns represent the mean linear ratio of four microarray experiments, and white columns the mean linear ratios of qRT–PCR. Numbers on the Y axis show the fold changes of gene expression levels. Data represented are : (A) Col6a1, (B) Fapb5, (C) Ftl1, (D) H3f3b, (E) Lox, (F) Prss23, (G) S100a11, (H) Sparc, (I) Sqstm1, and (J) Vim.

Functional classification of regulated genes

To analyse whether specific functional annotations were overrepresented among the regulated genes, EASE was used to classify the genes for two categories of GO terms: biological processes and molecular functions. The overrepresentation of nine molecular functions was detected (Table 1A): for example, catalytic and structural molecule activity or binding of calcium ions, nucleic acids, lipids, or proteins. GO term analysis of biological processes identified cell growth, development, nucleic acid metabolism, cell proliferation, and protein metabolism as over-represented (Table 1B). Thus, the upregulation of eight calcium-binding proteins suggests that altered intracellular signalling might be associated with constitutive Kras activation. Additionally, several genes functionally associated with cell growth, proliferation, development, and structural molecule activity indicate pathways involved in Kras-mediated tumour development and metastasis.
Table 1

Gene ontology

GO term Gene symbol
(A) Molecular functions  
Calcium–ion binding Anxa2, Anxa3, Anxa5, Fbln2, S100A11, S100A6, Sparc, Ssr4
Nucleic acid binding Nfic, RPl18, Runx3, Sfrs3, Snrpf, Zfp36l1
Catalytic activity Anxa3, Atp5a1, Cox7b, Lox, Rac1, Sod1
Transporter activity Atp5a1, Atp5 l, Cox7b, Fabp5, Sec61G
Structural molecule activity Col1a1, Fbln2, Rpl13a, Rpl18, Vim
Enzyme regulator activity Anxa2, Anxa3, anxa5, S100a6
Lipid binding Anxa2, Anxa3, Anxa5, Fabp5
Oxidoreductase activity Cox7b, Lox, Sod1
Protein binding S100A6, Sparc, Vim
  
(B) Biological processes  
Cell growth Atp5a1, Atp5 l, Fabp5, Nfic, Rac1, Runx3, S100a11, S100a6, Sec61 g, Ssr4, Zfp36l1
Development Anxa2, Col1a1, Cox7b, Fabp5, Rac1, S100a6, Sod1, Sparc
Nucleic acid metabolism Atp5a1, Atp5 l, Nfic, Runx3, S100a11, Sfrs3, Snrpf
Cell proliferation Nfic, Ras1, Runx3, S100a11, S100a6, Zfp36l1
Protein metabolism Lox, Rpl13a, Rpl18, Sec61g

Discussion

In this study, we focused specifically on the direct comparison of the global gene expression effects caused by mutations in codon 12 or 13 of the Kras proto-oncogene and Kras overexpression. In general, the significantly differentially expressed genes followed the same tendency of regulation in the three transfected cell lines. Yet, cluster analysis revealed more similarities between gene expression patterns of KrasG12V and KrasG13D transfectants compared with Krasoe cells. The level of cellular RNA was only elevated in Krasoe, whereas the amount of activated Ras molecules was increased in KrasG12V and KrasG13D cells. The differences in transcript expression patterns among the transfectants might be due to the mutation-mediated constitutive activation of Kras. In contrast, the overexpressed form of Kras still can switch from the activated to the non-activated state (Wittinghofer, 1998). There is clear evidence that the activation of the Raf/MAPK pathway is sufficient for oncogenic transformation mediated by Ras (Ellis and Clark, 2000). The expression of wt and mutant Kras alleles caused constitutive activation of this pathway as indicated by the phosphorylation status of Raf, Erk1, and Erk2 (Recktenwald ). Our microarray experiments detected no significant changes in gene expression levels of MAP kinases. However, for the overexpressed genes, Rac1 and Sparc regulatory effects in the MAP kinase pathways has been described (Frost ; Kato ). Proteome analysis of the transfected cell lines selected differentially expressed proteins at least 2-fold up- or downregulated compared with NIH3T3 cells (Recktenwald ). Up to 52 differentially expressed proteins were detected in the various Kras transfectants. Our expression profiling analysis identified 44 differentially expressed genes in at least two out of three transfectants (Krasoe, KrasG12V, and KrasG13D). In general, the overlapping transcripts and the proteins followed the same tendency of regulation in the different cell lines. Similar regulation in both transcriptome and proteome studies were found for Anxa5, S100a11, and Fapb5 in KrasG12V-transfectants as well as for Sod1 in Krasoe. Furthermore, the genes Lox and Col1a1, and the protein Hsp86 were reversely regulated between the Kras transfectants. However, a few proteins (eg, Anxa2) showed a reverse regulation compared with their transcripts. This comparison between differentially expressed proteins and transcripts suggests that changes at the protein level were associated in some cases with a corresponding transcriptional regulation. Several of the significantly regulated genes identified in our study were annotated with cellular functions such as cell growth (eg, Atp5a1, Fabp5, Runx, and S100a6) and cell death (eg, S100a11), angiogenesis (eg, Anxa2 and Zfp36l1), tumorigenesis (eg, Fabp5, Prss23, and Runx), and metastasis (eg, Lox and Sparc). Genes with very similar functional annotations were also regulated in expression studies of KrasG12V-transformed rat embryonic fibroblast (Tchernitsa ) in tumours derived from KrasG12V mouse embryonic fibroblasts (Vasseur ) and in a human colon adenoma cell line constitutive active Kras due to a mutation in codon 12 (Roberts ). These data suggest that independent of the cellular system and species background (mouse, rat, or human), the G12V mutation influences the regulation of the same cellular processes. Potential role of the regulated genes in tumour development and progression were also identified by GO analysis. The genes under the over-represented terms on structural molecular activity, cell growth, and cell proliferation include several genes directly annotated with tumorigenesis. For example, Runx3 was described as a tumour suppressor in gastric carcinogenesis (Peng ). Significant overexpression of transcript Zfp36l1 was found in lymph node and breast carcinomas (Abba ), and increased Fabp5 expression induces metastasis in human prostate carcinomas (Morgan ). Through such functional roles of genes differentially expressed by constitutive Kras activation or its overexpression, Kras potentially influence tumour progression. Angiogenesis is a cellular function whereby solid tumours recruit their own blood supply. In microarray studies, it was hypothesised that fibroblast secrete molecules that both promote and inhibit angiogenesis (Pollina ). Lox, Sparc, and Sod1 genes with copper-binding capacity have been associated with angiogenesis (Lane ; Juarez ; Shieh ). Those genes identified in our study to be associated with angiogenesis indicate pathways involved in Kras-mediated tumour development and metastasis. Different levels of aggressiveness in the transforming phenotype induced by mutations in Kras codons 12 or 13, and the overexpression of the Kras proto-oncogene in transfected tumour cells have been described (Guerrero ; Bazan ). In our study, activated Ras was stronger increased in KrasG12V than KrasG13D cells suggesting a diminished protein stability of the KrasG13D oncoprotein. It would be speculated that due to the possible switch from the activated to the non-activated state of overexpressed wt Kras, this overexpression has no influence on the amount of activated Ras molecules. Thus, despite many similarities in their oncogenic capacity the different mutant forms and overexpression of Kras may lead to a modulated activation of downstream targets that are responsible for these distinct oncogenic capacities. For example, the G12V mutation was more prevalent in metastatic human colorectal carcinoma than the codon 13 mutation (Al-Mulla ). The two genes, Lox and Col1a1, exhibiting either a reverse or non-regulation in the various transfectants may contribute to the different malignant phenotype. Despite the well-known physiological activity of Lox, its role in oncogenesis is quite controversially discussed. Elevated expression levels of Lox were detected in hypoxic human tumour cells (Erler ) and in invasive/metastatic human breast cancer cell lines (Payne ). However, reduced Lox levels were also observed in many cancers and cancer-derived cell lines (Csiszar ; Kaneda ). Additionally, Lox expression could inhibit the transforming activity of the Ras oncogene in NIH3T3 fibroblasts (Min ) suggesting a possible role of Lox as tumour suppressor (Di Donato ). Paradoxically, Lox expression is associated with both tumour suppression and tumour progression. Its role in tumorigenesis seems dependent on cellular location, cell type, and transformation status (Erler ). The lower expression of Lox in the KrasG12V-induced tumours may contribute to the higher aggressiveness of this mutation. In contrast, the upregulation of Lox in Krasoe transfectants could be interpreted as an important inhibitory factor of the transforming activity of Kras. The downregulation of type I collagen gene (Col1a1) is a common feature of Ras transformation (Thomas ). However, the overexpression of wt Ras itself is apparently not sufficient to reduce the expression of Col1a1 (Slack ). Decreased expression levels of Col1a1 were identified only in KrasG12V transfectants showing the highest Ras activity. Furthermore, no effects of wt Ras overexpression in rat fibroblasts on Col1a1 mRNA level were found (Slack ), whereas the gene was upregulated in Krasoe cells. We conclude that the overexpression of Col1a1 may suppress the transformed phenotype, whereas the downregulation of Col1a1 mediated by the codon 12 Kras mutation contributes to the neoplastic phenotype with the ability of tumour cells to metastasise. Identification and characterisation of genes differentially regulated by Kras overexpression and different Kras mutant forms should shed light on the understanding of how this oncogene regulates cell transformation and tumorigenesis.
  43 in total

1.  Significance analysis of microarrays applied to the ionizing radiation response.

Authors:  V G Tusher; R Tibshirani; G Chu
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-17       Impact factor: 11.205

Review 2.  Ras protein signalling.

Authors:  M F Olson; R Marais
Journal:  Semin Immunol       Date:  2000-02       Impact factor: 11.130

Review 3.  Microarray data normalization and transformation.

Authors:  John Quackenbush
Journal:  Nat Genet       Date:  2002-12       Impact factor: 38.330

4.  Somatic mutations of the lysyl oxidase gene on chromosome 5q23.1 in colorectal tumors.

Authors:  Katalin Csiszar; Sheri F T Fong; Aniko Ujfalusi; Stephen A Krawetz; Eugene P Salvati; James W Mackenzie; Charles D Boyd
Journal:  Int J Cancer       Date:  2002-02-10       Impact factor: 7.396

5.  Induction of SPARC by VEGF in human vascular endothelial cells.

Authors:  Y Kato; J M Lewalle; Y Baba; M Tsukuda; N Sakai; M Baba; K Kobayashi; S Koshika; Y Nagashima; F Frankenne; A Noël; J M Foidart; R I Hata
Journal:  Biochem Biophys Res Commun       Date:  2001-09-21       Impact factor: 3.575

Review 6.  The importance of being K-Ras.

Authors:  C A Ellis; G Clark
Journal:  Cell Signal       Date:  2000-07       Impact factor: 4.315

7.  K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression.

Authors:  S Guerrero; I Casanova; L Farré; A Mazo; G Capellà; R Mangues
Journal:  Cancer Res       Date:  2000-12-01       Impact factor: 12.701

8.  Inhibition of the growth and metastasis of human colon cancer by restoration of RUNX3 expression in cancer cells.

Authors:  Zhihai Peng; Huamei Tang; Xiaoliang Wang; Chongzhi Zhou; Junwei Fan; Liwei Wang; Zhiliang Jia; Qiang Li; Xiangdong Le; Daoyan Wei; Keping Xie
Journal:  Int J Oncol       Date:  2008-11       Impact factor: 5.650

9.  Regulating the angiogenic balance in tissues.

Authors:  Elizabeth A Pollina; Aster Legesse-Miller; Erin M Haley; Tracy Goodpaster; Julie Randolph-Habecker; Hilary A Coller
Journal:  Cell Cycle       Date:  2008-07-01       Impact factor: 4.534

10.  Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype.

Authors:  V Bazan; M Migliavacca; I Zanna; C Tubiolo; N Grassi; M A Latteri; M La Farina; I Albanese; G Dardanoni; S Salerno; R M Tomasino; R Labianca; N Gebbia; A Russo
Journal:  Ann Oncol       Date:  2002-09       Impact factor: 32.976

View more
  11 in total

1.  Label-free quantitative proteomics and N-glycoproteomics analysis of KRAS-activated human bronchial epithelial cells.

Authors:  Putty-Reddy Sudhir; Chein-Hung Chen; Madireddy Pavana Kumari; Mei-Jung Wang; Chih-Chiang Tsou; Ting-Yi Sung; Jeou-Yuan Chen; Chung-Hsuan Chen
Journal:  Mol Cell Proteomics       Date:  2012-07-03       Impact factor: 5.911

Review 2.  The molecular basis of chemoradiosensitivity in rectal cancer: implications for personalized therapies.

Authors:  Marian Grade; Hendrik A Wolff; Jochen Gaedcke; B Michael Ghadimi
Journal:  Langenbecks Arch Surg       Date:  2012-03-02       Impact factor: 3.445

3.  PTTG acts as a STAT3 target gene for colorectal cancer cell growth and motility.

Authors:  C Zhou; Y Tong; K Wawrowsky; S Melmed
Journal:  Oncogene       Date:  2013-02-18       Impact factor: 9.867

4.  Personalizing colon cancer therapeutics: targeting old and new mechanisms of action.

Authors:  Christina Leah B Kline; Wafik S El-Deiry
Journal:  Pharmaceuticals (Basel)       Date:  2013-08-21

5.  KRAS induces lung tumorigenesis through microRNAs modulation.

Authors:  Lei Shi; Justin Middleton; Young-Jun Jeon; Peter Magee; Dario Veneziano; Alessandro Laganà; Hui-Sun Leong; Sudhakar Sahoo; Matteo Fassan; Richard Booton; Rajesh Shah; Philip A J Crosbie; Michela Garofalo
Journal:  Cell Death Dis       Date:  2018-02-13       Impact factor: 8.469

6.  NRAS mutant E132K identified in young-onset sporadic colorectal cancer and the canonical mutants G12D and Q61K affect distinct oncogenic phenotypes.

Authors:  Ryan Timothy D Yu; Reynaldo L Garcia
Journal:  Sci Rep       Date:  2020-07-03       Impact factor: 4.379

7.  From basic researches to new achievements in therapeutic strategies of KRAS-driven cancers.

Authors:  Mahsa Saliani; Razieh Jalal; Mohammad Reza Ahmadian
Journal:  Cancer Biol Med       Date:  2019-08       Impact factor: 4.248

8.  Regulation of KRAS protein expression by miR-544a and KRAS-LCS6 polymorphism in wild-type KRAS sporadic colon adenocarcinoma.

Authors:  Sonja Marinović; Anita Škrtić; Tina Catela Ivković; Mirko Poljak; Sanja Kapitanović
Journal:  Hum Cell       Date:  2021-07-07       Impact factor: 4.174

9.  eVIP2: Expression-based variant impact phenotyping to predict the function of gene variants.

Authors:  Alexis M Thornton; Lishan Fang; April Lo; Maria McSharry; David Haan; Casey O'Brien; Alice H Berger; Marios Giannakis; Angela N Brooks
Journal:  PLoS Comput Biol       Date:  2021-07-02       Impact factor: 4.475

10.  KRAS mutant rectal cancer cells interact with surrounding fibroblasts to deplete the extracellular matrix.

Authors:  Jin K Kim; Michael R Marco; Seo-Hyun Choi; Xuan Qu; Chin-Tung Chen; Moshe Elkabets; Lauren Fairchild; Oliver Chow; Francisco M Barriga; Lukas E Dow; Kevin O'Rourke; Bryan Szeglin; Dmitry Yarilin; Sho Fujisawa; Katia Manova-Todorova; Philip B Paty; Jinru Shia; Christina Leslie; J Joshua Smith; Scott Lowe; Raphael Pelossof; Francisco Sanchez-Vega; Julio Garcia-Aguilar
Journal:  Mol Oncol       Date:  2021-06-15       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.